HALOZYME THERAPEUTICS, INC. (HALO) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for HALOZYME THERAPEUTICS, INC. (HALO): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 67/100 — a percentile rank of HALOZYME THERAPEUTICS, INC.’s fundamentals against Manufacturing peers, weakest on valuation. A quality ranking, not a price prediction.
| Market cap | $12.1B |
| P / E | 29.4× |
| P / S | 7.3× |
| EV / EBITDA | 13.5× |
| Gross margin | 82.4% |
| Operating margin | 38.8% |
| Net margin | 24.9% |
| Return on equity | 288.1% |
| ROIC | 21.5% |
| Revenue growth | 41.2% |
| Debt / equity | 14.9× |
| Dividend yield | 0.0% |
Is HALOZYME THERAPEUTICS, INC. overvalued? P/E looks overvalued vs its 5-year range; P/S looks fair vs its 5-year range; EV/EBITDA looks fair vs its 5-year range; P/B looks overvalued vs its 5-year range.
Independent of the events above — derived from HALOZYME THERAPEUTICS, INC.’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact